eclalbasaponin I: has antineoplastic activity; isolated from Eclipta prostrata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Eclipta | genus | A plant genus of the family ASTERACEAE. Members contain wedelolactone.[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 10079039 |
| CHEMBL ID | 3343908 |
| MeSH ID | M0584285 |
| Synonym |
|---|
| eclalbasaponin i |
| 158511-59-2 |
| CHEMBL3343908 , |
| eclalbasaponin i, analytical standard |
| bdbm50235144 |
| HY-N7022 |
| CS-0101588 |
| MS-31467 |
| [(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4ar,5r,6ar,6as,6br,8ar,10s,12ar,14bs)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradec |
| E88622 |
| DTXSID501316627 |
| AKOS040760374 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eclalbasaponin II treatment dose-dependently increased sub G" | ( Eclalbasaponin II induces autophagic and apoptotic cell death in human ovarian cancer cells. Cho, YJ; Choi, JH; Jang, DS; Lee, JS; Lee, KT; Woo, JH, 2016) | 2.6 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tissue factor | Homo sapiens (human) | IC50 (µMol) | 0.0096 | 0.0001 | 0.7344 | 10.0000 | AID1436859 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| serine-type endopeptidase activity | Tissue factor | Homo sapiens (human) |
| protease binding | Tissue factor | Homo sapiens (human) |
| protein binding | Tissue factor | Homo sapiens (human) |
| phospholipid binding | Tissue factor | Homo sapiens (human) |
| cytokine receptor activity | Tissue factor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Tissue factor | Homo sapiens (human) |
| plasma membrane | Tissue factor | Homo sapiens (human) |
| external side of plasma membrane | Tissue factor | Homo sapiens (human) |
| cell surface | Tissue factor | Homo sapiens (human) |
| membrane | Tissue factor | Homo sapiens (human) |
| collagen-containing extracellular matrix | Tissue factor | Homo sapiens (human) |
| serine-type peptidase complex | Tissue factor | Homo sapiens (human) |
| plasma membrane | Tissue factor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1172858 | Inhibition of NFkappaB (unknown origin) expressed in in LPS-stimulated HEK293-NF-kappaB-luc cells assessed as luminescence signals measured by relative light units at 1 ug/mL pre-treated for 4 hrs before LPS challenge for 24 hrs by luciferase assay | 2014 | Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22 | Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate. |
| AID1172859 | Inhibition of NFkappaB (unknown origin) expressed in in LPS-stimulated HEK293-NF-kappaB-luc cells assessed as luminescence signals measured by relative light units at 10 ug/mL pre-treated for 4 hrs before LPS challenge for 24 hrs by luciferase assay | 2014 | Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22 | Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate. |
| AID1172860 | Inhibition of NFkappaB (unknown origin) expressed in in LPS-stimulated HEK293-NF-kappaB-luc cells assessed as luminescence signals measured by relative light units at 100 ug/mL pre-treated for 4 hrs before LPS challenge for 24 hrs by luciferase assay | 2014 | Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22 | Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate. |
| AID1436859 | Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Microbial hydroxylation and glycosylation of pentacyclic triterpenes as inhibitors on tissue factor procoagulant activity. |
| AID1172861 | Inhibition of NFkappaB (unknown origin) expressed in in LPS-stimulated HEK293-NF-kappaB-luc cells assessed as luminescence signals measured by relative light units at 500 ug/mL pre-treated for 4 hrs before LPS challenge for 24 hrs by luciferase assay | 2014 | Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22 | Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||